NICE Rejects Opdivo for Renal Cell Carcinoma

July 11, 2016

The UK’s National Institute for Health and Care Excellence declined to recommend Bristol-Myers Squibb’s Opdivo for reimbursement in the treatment of advanced renal cell carcinoma.

The cost watchdog cited uncertainty about the drug’s long-term benefit, writing that clinical trial data submitted by the company were “immature.”

Specifically, NICE determined that it was unlikely that many patients would live five additional years from the treatment, which costs roughly $570 for a 40-mg vial and around $1,430 for a 100-mg vial.

View today's stories